Rituximab (Rituxan) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the trea™ent of hematological cancers and autoimmune diseases. When Rituximab binds to CD20 on the surface of normal and malignant B cells, natural killer (NK) cells is activated to destroy these B cells. It is therefore used to treat diseases with too many B cells, overactive B cells, or dysfunctional B cells. Anti-Rituximab Antibody (17B6), mAb, Mouse is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Rituximab.